|
|
|
|
 |
Corporate Profile
Æterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options.
Contact us:
Æterna Zentaris Inc.
1405 du Parc-Technologique Blvd.
Québec, Québec
Canada
G1P 4P5
Phone: (418) 652-8525
Fax: (418) 652-0881
www.aezsinc.com
|
 |
|
|
Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting more...>
Aeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco more...>
|
 |
|
Thursday February 2, 2012
ASCO Genitourinary Cancers Symposium
More
|
|
|
Download PDF (67K) |
| Download and install Acrobat Reader 6.0. |
|
|
|
